BUSINESS INSIGHTS, PHARMACY MARKET
Xeris Pharmaceuticals, Inc. | January 31, 2023
On January 30, 2023, Xeris Biopharma Holdings, Inc., a leading biopharmaceutical company, announced that the Food and Drug Administration (FDA) granted orphan-drug exclusivity (ODE) to its subsidiary Xeris Pharmaceuticals, Inc. for Recorlev® (levoketoconazole) a cortisol synthesis inhibitor for the treatment of endogenous Cushing's syndrome in adult patients for whom surgery is not viable or has not been effective.
levoketoconazole (Recorlev) being the first FDA-approved therapeutic for the treatment of endogenous hypercortisolemia, Xeris Pharmaceutical is permitted to have seven years of orphan-drug market exclusivity beginning from December 30, 2021. The FDA's Orphan Drug Designation program intends to accelerate the development of medications that treat a disease that affects 200,000 or fewer people in the United States each year. This regulatory exclusivity with the patent exclusivity under Xeris' U.S. patents for Recorlev is valid until at least March 2040.
To serve and assist this community, Xeris is dedicated to ensuring that everyone who needs access to their medications receives them. Xeris has developed Xeris CareConnection™ to provide patients and caregivers with a comprehensive program that includes financial support, one-on-one assistance, and educational materials throughout the treatment journey. Additionally, Xeris CareConnection assists healthcare providers and their teams with education on access and reimbursement.
About Xeris Pharmaceuticals, Inc.
Founded in 2005, Xeris is a growth-oriented biopharmaceutical firm dedicated to improving patients' lives via the development and commercialization of novel products in a range of therapies. Its unique technology makes medicines easier to use for patients & caregivers. The company has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for treating severe hypoglycemia (very low blood sugar); Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous hypercortisolemia. In addition, it has an increasingly broad pipeline of research and partnered projects utilizing its unique formulation technology platforms, XeriSol™ and XeriJect™, bringing forward innovative products for the firm and its partners.
Read More
BUSINESS INSIGHTS, PHARMA TECH
West Pharmaceutical Services | February 13, 2023
West Pharmaceutical Services, Inc., a leading global innovative injectable drug administration solutions provider, recently announced the expansion of its remarkable collaboration with Corning Incorporated, which now includes exclusive distribution rights for Corning Valor® Glass vials as well as the launch of its first product, West Ready Pack™ with Corning Valor® RTU Vials employing SG EZ-fill® technology.
The West Ready Pack™ with Corning Valor® RTU Vials integrates West's highest quality NovaPure® stoppers, Flip-Off® CCS (Certified, Clean, Sterilized) seals and Corning's best-in-class Valor® RTU Vials with SG EZ-fill® technology into a complete containment solution to assist in the introduction of parenteral drugs and diagnostics to the market.
West announced its agreement with Corning in January 2022, which includes a multimillion-dollar investment to develop Corning's Valor® Glass technology to improve patient safety and increase access to life-saving therapies. This strategic alliance provides premier elastomer-glass system solutions for injectable drug storage and delivery. In addition, West and Corning intend to collaborate to develop the next generation of integrated packaging and delivery system solutions.
Valor® RTU Vials with SG EZ-fill® technology improve medication storage and distribution, enable more reliable access to important medicines for public health, and maximize production efficiency. This pharmaceutical glass was explicitly created to handle the problems of modern industrial procedures.
The Ready Pack™ mixture of NovaPure® stoppers, Flip-Off® CCS seals, and Valor® RTU Vials with SG EZ-fill® technology offers drug developers the following advantages
Proven Container Closure Integrity (CCI), which includes the ability to sustain cold storage CCI when cooled to and kept at -80 degrees Celsius;
Ready-to-use sterile format that may be introduced immediately into filling operations, avoiding the requirement for component preparation;
Premium components with the most stringent particle requirements available from West; and
Availability in volumes appropriate for small-scale filling operations with continuity to quantity alternatives for large-scale commercial operations.
About West Pharmaceutical Services
Founded in 1923, West Pharmaceutical Services, Inc. is a leading high-quality, innovative injectable solutions and services provider. It is a trusted partner to both established and emergent drug producers and contributes to the safe, effective containment and delivery of life-enhancing and life-saving medications to patients. West supports its clients by supplying over 45 billion components and devices each year, with a team of approximately 10000 members spread across 50 facilities globally. Headquartered in Exton, Pennsylvania, the company has been operating for over a century and achieved $2.83 billion in net sales in the fiscal year 2021.
Read More
BUSINESS INSIGHTS, PHARMACY MARKET
Horus Pharma | January 11, 2023
On January 10, 2023, Horus Pharma, an independent French ophthalmology laboratory known for its preservative-free eye and eyelid health products, announced a partnership with Plastic Bank to recycle approximately 100 tons of plastic annually.
The pact is a part of Horus Pharma's environmental program, Eco' Ophtalmo. Since its founding in 2003, corporate social responsibility (CSR) has been a consistent part of Horus Pharma's culture. Over the years, the company's increasing awareness of industrial activities' environmental impact has led to numerous initiatives.
Horus Pharma has committed to continuously seeking new solutions via innovation and collaboration to minimize its ecological footprint to the greatest extent possible. Furthermore, through its strategy of cooperative actions and initiatives, it strives to encourage and support the spread of ecologically-responsible practices within its industry.
Launched in September 2022, the Eco' Ophtalmo initiative has incorporated ecology into Horus Pharma's culture and strategy planning. Eco' Ophtalmo project encompasses major and ambitious initiatives, including an environmental and social commitment to achieve Plastic Net Zero and create recyclable packaging. In addition, Horus Pharma aims to promote awareness among ophthalmologists and drive action by cooperating to increase awareness and encourage collective efforts to reduce the environmental footprint.
About Horus Pharma
Founded in 2003, Horus Pharma is a leading eye and eyelid health product developer. It operates in most ophthalmology segments to develop effective and safe practical innovations. Focused on patient safety, its laboratories are renowned for their expertise in developing preservative-free formulations and product delivery systems. The laboratory's product portfolio includes medicinal products, food supplements, and medical devices. In addition, it has been pursuing growth with its new surgery division by providing surgical and peri-surgical diagnostic solutions for eye problems.
Read More